engleski

Genotyping CYP2D6 in head and neck cancer patients by Multiplex Allele Specific PCR

We investigated the possible association of bearing the Cytochrome P450 CYP2D6 null alleles (CYP2D6*3, *4, *5, *6, *7, and *8) with tumors in patients having head and neck cancer (HNC). It is known that persons bearing two null alleles poorly metabolize some common drugs (Poor Metabolizer Phenotype – PM) as well as other foreign and carcinogenic substances. Persons with only one disrupted CYP2D6 gene (bearing one normal and one null allele) are considered to be Intermediate metabolizer phenotype (IM). We genotyped 64 controls, and 39 HNC patients by Multiplex Allele Specific PCR on whole blood DNA. Study results showed allelic frequencies for *3, *4 and *6 alleles (only alleles observed) in controls to be 1.6%, 14.1% and 0.8%, respectively; among them we found 4.7% PMs and 23.4% IMs. In cancer patient’s group allelic frequencies for *3 and *4 were 2.8% and 19.4% respectively, and no other alleles were found. We also did not find any PM but only IM phenotype (44.4%). Results of our study showed statistically significant difference for genotype frequencies (Chi-square; p=0.007) and predicted phenotype (Chi-square; p=0.001). To confirm our findings assuming poor metabolizer phenotype as a protective factor for development of head and neck cancer, further study on larger group is needed.

CYP2D6 gene; head and neck cancer

nije evidentirano